Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2003
11/20/2003WO2003094926A1 Fluorescent sensor compounds for detecting saccharides
11/20/2003WO2003094925A1 Injectable bisphosphonate formulations
11/20/2003WO2003094923A1 COMBINATION OF AN HMG-CoA REDUCTASE INHIBITOR AND A NITRATE ESTER
11/20/2003WO2003094922A1 Use of cisplatin in combination with folic acid for increasing cisplatin efficacy
11/20/2003WO2003094921A2 Utilization of inhibitors of egfr-mediated signal transduction for the treatment of benign prostatic hyperplasia (bph)/prostatic hypertrophy
11/20/2003WO2003094920A1 Microbicidal pyrimidine or triazine for preventing sexual hiv transmission
11/20/2003WO2003094919A2 Novel crystalline forms of gatifloxacin
11/20/2003WO2003094918A1 Substituted piperazine as melanocortin receptors ligands
11/20/2003WO2003094917A1 Vintoperol-containing medicinal composition for transdermal administration
11/20/2003WO2003094916A1 Methods of using thiazolidine derivatives to treat cancer or inflammation
11/20/2003WO2003094915A1 Use of valsartan ot its metabolite to inhibit platelet aggregation
11/20/2003WO2003094914A1 Substantially pure solid form of the enol tautomer of 3-indolylpyruvic acid for use in the treatment of central nervous system disturbances
11/20/2003WO2003094913A1 Use of 2-oxo-1-pyrrolidone derivatives for the preparation of a drug
11/20/2003WO2003094912A1 Bislactone derivative and use thereof in medicinal composition
11/20/2003WO2003094911A1 Hepatoprotective activity of 10-o-p-hydroxybenzoyiaucubin
11/20/2003WO2003094910A1 Use of 8-prenylflavanones for anti-angiogenesis therapy and for fibrinolytic therapy
11/20/2003WO2003094908A1 A pharmaceutical composition for the treatment of seborrhea containing 4-hydroxy-5-methoxy-4-[2-methyl-3(3-methyl-2-butenyl)-2-oxiranyl]-1-oxaspiro[2,5]octan-6-one
11/20/2003WO2003094907A1 Cell proliferating agents
11/20/2003WO2003094906A1 Anti-rhinovirus active agents
11/20/2003WO2003094905A1 Diclofenac-based composition for the topical treatment of oropharyngeal cavity disorders
11/20/2003WO2003094904A1 Methods and compositions for the treatment of graft failure
11/20/2003WO2003094903A1 A method of treatment
11/20/2003WO2003094902A2 Surface treatment of sars-infected lungs
11/20/2003WO2003094901A1 Medicament for treating and preventing pneumoconiosis
11/20/2003WO2003094897A1 Photostabilized soft capsule
11/20/2003WO2003094896A1 A method to improve surface properties of pharmaceutical tablets
11/20/2003WO2003094895A1 Extended release tablets comprising felodipine
11/20/2003WO2003094894A1 Nanoparticulate nystatin formulations
11/20/2003WO2003094892A1 Conversion of amorphous material to a corresponding crystalline material by spray drying and utilization of the crystalline spray dried material in drug formulations
11/20/2003WO2003094890A1 Capsules for dry powder inhalers and methods of making and using same
11/20/2003WO2003094889A1 Lyophilization product
11/20/2003WO2003094888A1 Processes for forming a drug delivery device
11/20/2003WO2003094881A1 Composition and the use thereof as a pharmaceutical or cosmetic formulation for external use
11/20/2003WO2003094878A1 Gallocatechin gallate-containing composition
11/20/2003WO2003094864A2 Novel polyol-glycoside compositions for the skin
11/20/2003WO2003094861A2 Bis-benzimidazoles and related compounds as potassium channel modulators
11/20/2003WO2003094859A2 Epha2 monoclonal antibodies and methods of use thereof
11/20/2003WO2003094853A2 Compositions and methods for combating lower urinary tract dysfunctions with delta opioid receptor agonists
11/20/2003WO2003094850A2 Lipid a and other carbohydrate ligand analogs
11/20/2003WO2003094842A2 Conjugates comprising central nervous system active drug
11/20/2003WO2003094840A2 Induction of antigen specific immunologic tolerance
11/20/2003WO2003094839A2 Pyrimidinone compounds, compositions and methods
11/20/2003WO2003094837A2 Treatments with autologous fibroblast
11/20/2003WO2003094836A2 Methods and products for enhancing immune responses using imidazoquinoline compounds
11/20/2003WO2003094831A2 Novel diazabicyclic biaryl derivatives
11/20/2003WO2003094830A2 Novel azacyclic ethynyl derivatives
11/20/2003WO2003094829A2 Pathogen vaccines and methods for using the same
11/20/2003WO2003094812A1 Abuse-resistant opioid solid dosage form
11/20/2003WO2003094616A1 Antibacterial
11/20/2003WO2003087062A3 4-(heterocyclyl)-benzenesulfoximine compounds for the treatment of inflammation
11/20/2003WO2003084479A3 Large scale methods of producing adenovirus and adenovirus seed stocks
11/20/2003WO2003072016A3 Pharmaceutical compositions in particulate form
11/20/2003WO2003070745A3 Carbonate and carbamate modified forms of glucocorticoids
11/20/2003WO2003070192A9 Compositions and methods for surrogate antibody modulation of an immune response and transport
11/20/2003WO2003066572B1 Polyamine compounds and compositions for use in conjunction with cancer therapy
11/20/2003WO2003066023A9 A stable pharmaceutical formulation comprising torsemide modification ii
11/20/2003WO2003065971A9 Non-myeloablative tolerogenic treatment with tyrphostins
11/20/2003WO2003065970A3 Treatment of fibromyalgia and related fatigue syndromes using pindolol
11/20/2003WO2003063764A3 6-SUBSTITUTED PYRAZOLO [3,4-d] PYRIMIDIN-4-ONES USEFUL AS CYCLIN DEPENDENT KINASE INHIBITORS
11/20/2003WO2003063681A3 Method and compound for the prophylaxis or treatment of an immunodeficiency condition, such as aids
11/20/2003WO2003061696A3 Systems and methods for photodynamic therapy
11/20/2003WO2003057173A3 Broad spectrum inhibitors
11/20/2003WO2003055915A3 Human netrin receptor and uses thereof
11/20/2003WO2003054012A3 Leptin proteins
11/20/2003WO2003053352A3 Therapeutic compounds for treating dyslipidemic conditions
11/20/2003WO2003051276A3 Therapeutic heterocycles
11/20/2003WO2003050504A3 Methods and compositions to treat cardiovascular disease usin g 1419, 58765 and 2201
11/20/2003WO2003049772A3 Guanidinium transport reagents and conjugates
11/20/2003WO2003048130A3 Peroxisome proliferator activated receptor agonists
11/20/2003WO2003041647A3 Synthesis and purification of valacyclovir
11/20/2003WO2003041632A3 Eutectic-based self-nanoemulsified drug delivery system
11/20/2003WO2003040399A3 Therapeutic methods for nucleic acid delivery vehicles
11/20/2003WO2003039465A3 Treating canker sores with patches to speed healing and relieve pain
11/20/2003WO2003038109A3 Method for the inhibition of methanogenesis
11/20/2003WO2003032984A8 2-phenyl benzimidazoles and imidazo-[4,5]-pyridines as cdsi/chk2-inhibitors and adjuvants to chemotherapy or radiation therapy in the treatment of cancer
11/20/2003WO2003032914A3 Methods for treating substance abuse with cholinesterase inhibitors
11/20/2003WO2003029210A3 Heteroaryl substituted tetrazole modulators of metabotropic glutamate receptor-5
11/20/2003WO2003028665A3 Methods for the purification of levofloxacin
11/20/2003WO2003028664A3 Preparation of levofloxacin and forms thereof
11/20/2003WO2003027076A3 1h-imidazole derivatives having cb1 agonistic, cb1 partial agonistic or cb1- antagonistic activity
11/20/2003WO2003026565A3 Composition and treatment method for brain and spinal cord injuries
11/20/2003WO2003024403A3 Carbohydrate supplementation and rehydration composition
11/20/2003WO2003024394A3 Method of treating benign prostatic hyperplasia and other beingn porstate conditions
11/20/2003WO2003024357A3 Microfabricated nanopore device for sustained release of therapeutic agent
11/20/2003WO2003022804A3 Method for the preparation of crystalline tetrahydrobenzothiepines
11/20/2003WO2003020210A3 Vaginal delivery of chemotherapeutic agents and inhibitors of membrane efflux systems for cancer therapy
11/20/2003WO2003018075A3 Transdermal therapeutic system with fentanyl or related substances
11/20/2003WO2003017946A3 Non-oxidatively metabolized compounds and compositions, synthetic pathways therefor, and uses thereof
11/20/2003WO2003014105A9 Bicyclic compound, production and use as hiv inhibitors
11/20/2003WO2003014079A8 Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments
11/20/2003WO2003013512A3 Crystalline forms of fluvastatin sodium
11/20/2003WO2003012093A3 Regulator of calcineurin
11/20/2003WO2003007970A3 Use of magnesium for preventing in-stent thrombosis and complications after arterial angioplasty with stent placement
11/20/2003WO2003006509A3 Human mini-antibody cytotoxic for tumor cells which express the erbb2 receptor
11/20/2003WO2003006447A3 Interaction inhibitors of tcf-4 with beta-catenin
11/20/2003WO2003001982A3 Physiological tissue repair and functional organ regeneration by cultivation of regenerative stem cells in vivo and in situ
11/20/2003WO2003000699A8 Substituted 1-oxa-2,8-diaza-spiro[4,5]dec-2-ene derivatives as medicaments for the treatment of pain
11/20/2003WO2003000021A3 Pancam nucleic acids and polypeptides
11/20/2003WO2002102315A3 QUINAZOLINE AND PYRIDO[2,3-d]PYRIMIDINE INHIBITORS OF PHOSPHODIESTERASE (PDE) 7
11/20/2003WO2002101045A3 Vanilloid receptor-related nucleic acids and polypeptides
1 ... 5268 5269 5270 5271 5272 5273 5274 5275 5276 5277 5278 5279 5280 5281 5282 5283 5284 5285 5286 5287 5288 ... 7860